Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Malignant Solid Tumor

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,056 result(s) found for: Malignant Solid Tumor. Displaying page 53 of 53.
    «« First « Previous 45  46  47  48  49  50  51  52  53 
    EudraCT Number: 2020-004264-26 Sponsor Protocol Number: VS-6766-201 Start Date*: 2021-07-09
    Sponsor Name:Verastem, Inc.
    Full Title: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP 201)
    Medical condition: Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Trial now transitioned) BE (Trial now transitioned) ES (Restarted) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-017270-21 Sponsor Protocol Number: TCD11420 Start Date*: 2010-04-28
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: Randomized phase 2 study of gemcitabine/cisplatin with or without SAR240550 (BSI-201), a PARP1 inhibitor, in patients with stage IV non-small cell lung cancer
    Medical condition: Non-small cell lung cancer stage IV.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10029522 Non-small cell lung cancer stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) ES (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-000211-64 Sponsor Protocol Number: H9H-MC-JBAJ Start Date*: 2011-07-26
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 1b/2 Study with Gemcitabine and LY2157299 for Patients with Metastatic Cancer (Phase 1b) and Advanced or Metastatic Unresectable Pancreatic Cancer (Phase 2)
    Medical condition: Phase 1b: Metastatic Cancer Phase 2: Advanced or Metastatic Unresectable Pancreatic Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) BE (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2022-002265-15 Sponsor Protocol Number: BO44157 Start Date*: 2023-03-27
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE II, RANDOMIZED, MULTICENTER, OPEN LABEL, CONTROLLED STUDY OF RO7247669 ALONE OR IN COMBINATION WITH TIRAGOLUMAB VERSUS ATEZOLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED OR...
    Medical condition: Previously Untreated Locally Advanced or Metastatic Urothelial Bladder Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10046714 Urothelial carcinoma bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) GR (Trial now transitioned) DK (Trial now transitioned) IT (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-003101-58 Sponsor Protocol Number: 849-007 Start Date*: 2021-03-02
    Sponsor Name:MIRATI THERAPEUTICS INCORPORATED
    Full Title: A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation
    Medical condition: Advanced Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) HU (Trial now transitioned) BE (Trial now transitioned) AT (Trial now transitioned) PT (Trial now transitioned) PL (Trial now transitioned) CZ (Trial now transitioned) BG (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-006537-40 Sponsor Protocol Number: VEG108838 Start Date*: 2008-01-22
    Sponsor Name:GlaxoSmithkline Research & Development Limited
    Full Title: A Randomized, Multicenter, Phase III Study Comparing the Combination of Pazopanib and Lapatinib versus Lapatinib Monotherapy in Patients with ErbB2 over-expressing Inflammatory Breast Cancer
    Medical condition: Relapsed or refractory inflammatory breast cancer with ErbB2 tumours.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021974 Inflammatory breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) BE (Completed) DE (Prematurely Ended) GB (Completed) FR (Completed) ES (Completed) IT (Completed) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-005135-23 Sponsor Protocol Number: MK-7684A-006 Start Date*: 2022-03-31
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: Open-label Phase 3 Study of MK-7684A (Coformulation of Vibostolimab with Pembrolizumab) in Combination with Concurrent Chemoradiotherapy followed by MK-7684A Versus Concurrent Chemoradiotherapy fol...
    Medical condition: Unresectable, locally advanced, Stage III non-small cell lung cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10029514 Non-small cell lung cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Trial now transitioned) IT (Trial now transitioned) PT (Trial now transitioned) GR (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-000974-25 Sponsor Protocol Number: 61186372NSC2005 Start Date*: 2023-04-12
    Sponsor Name:Janssen-Cilag International NV
    Full Title: Evaluation of Amivantamab Infusion Related Reaction Mitigation
    Medical condition: EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-000062-20 Sponsor Protocol Number: 3066K1-404-WW Start Date*: 2007-11-22
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc. Global Medical Affairs
    Full Title: A Randomized Trial of Temsirolimus and Sorafenib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma Who Have Failed First-Line Sunitinib Therapy
    Medical condition: Patients With Advanced Renal Cell Carcinoma Who Have Failed First-Line Sunitinib Therapy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) HU (Completed) DE (Completed) SE (Completed) FI (Completed) NL (Completed) ES (Completed) GB (Completed) AT (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-002549-39 Sponsor Protocol Number: Ponatinib-1501 Start Date*: 2020-12-07
    Sponsor Name:Takeda Development Center Americas, Inc.
    Full Title: A Pivotal Phase 1/2, Single-Arm, Open-label Study to Evaluate the Safety and Efficacy of Ponatinib With Chemotherapy in Pediatric Patients With Philadelphia Chromosome-Positive (Ph+) Acute Lympho...
    Medical condition: acute lymphoblastic leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) CZ (Completed) NL (Prematurely Ended) IT (Prematurely Ended) PL (Prematurely Ended) PT (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-005405-26 Sponsor Protocol Number: MK-3475-06A Start Date*: 2022-07-25
    Sponsor Name:MERCK SHARP & DOHME LLC. UNA SUSSIDIARIA DI MERCK & CO. INC.
    Full Title: A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer naïve to PD-1/PD-L1 Treatment (KEYMAKER...
    Medical condition: Esophageal Squamous Cell Carcinoma (ESCC)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10030186 Oesophageal squamous cell carcinoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-005443-76 Sponsor Protocol Number: MK-3475-06B Start Date*: 2022-07-14
    Sponsor Name:MERCK SHARP & DOHME LLC. UNA SUSSIDIARIA DI MERCK & CO. INC.
    Full Title: A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to PD-1/PD-L1 Treatm...
    Medical condition: Esophageal Squamous Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10030186 Oesophageal squamous cell carcinoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-022620-77 Sponsor Protocol Number: AB10006 Start Date*: 2013-07-15
    Sponsor Name:AB Science
    Full Title: A prospective, multicentre, open-label, randomised, uncontrolled, phase 1/2 study to evaluate efficacy and safety of masitinib in combination with etoposide, or masitinib in combination with irinot...
    Medical condition: hepatocellular carcinoma
    Disease: Version SOC Term Classification Code Term Level
    12.1 10019830 Hepatocellular carcinoma resectable LLT
    12.1 10019828 Hepatocellular carcinoma non-resectable LLT
    12.1 10019829 Hepatocellular carcinoma recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Completed) SK (Prohibited by CA) CZ (Completed) GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-004380-31 Sponsor Protocol Number: CM-2013-01 Start Date*: 2015-01-22
    Sponsor Name:Cell Medica Inc.
    Full Title: A Phase 2 open label study to investigate the efficacy of autologous EBV-specific T-cells for the treatment of patients with aggressive extranodal NK/T-cell lymphoma (ENKTCL).
    Medical condition: Aggressive EBV positive extranodal NK/T-cell lymphoma (ENKTCL)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10034623 Peripheral T-cell lymphoma unspecified PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-003083-21 Sponsor Protocol Number: GO29431 Start Date*: 2015-08-20
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH A PLATINUM AGENT (CISPLATIN OR CARBOPLATIN) IN COMBINATION WITH EITHER PEMETREXED OR GEMCITABINE FOR ...
    Medical condition: Stage IV Non-Squamous or Squamous Non−Small Cell Lung Cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) CZ (Prematurely Ended) ES (Ongoing) GR (Completed) FR (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-003774-15 Sponsor Protocol Number: A6181077 Start Date*: 2007-08-09
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, 10017, United States
    Full Title: A RANDOMIZED PHASE 2 STUDY OF SU011248 VERSUS STANDARD-OF-CARE FOR PATIENTS WITH PREVIOUSLY TREATED, ADVANCED, TRIPLE RECEPTOR NEGATIVE (ER, PR, AND HER2) BREAST CANCER
    Medical condition: Histologically or cytologically proven diagnosis of breast cancer with evidence of 1) unresectable, locally recurrent, or 2) metastatic disease. Documentation of estrogen and progestin receptor (ER...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Prematurely Ended) CZ (Prematurely Ended) DE (Prematurely Ended) IT (Prematurely Ended) HU (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 45  46  47  48  49  50  51  52  53 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jun 24 02:17:14 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA